SRT1720 is an inhibitor of sirtuin 3 (SIRT3) and activator of sirtuin 1 (SIRT1); sirtuins are considered class III histone deacetylases (HDACs). SRT1720 exhibits nephroprotective, anti-aging, anti-inflammatory, and pro-angiogenic activities. SRT1720 binds the acetyl-Lys site on sirtuins rather than the NAD+ site. In animal models of kidney ischemia/reperfusion injury, SRT1720 improves renal tubular pathology and overall renal function. In animal models fed high fat diets, SRT1720 delays the onset of metabolic diseases and decreases levels of pro-inflammatory cytokines, extending animal lifespan. In animal models of macular degeneration, this compound suppresses activation of NF-B and release of IL-6, IL-8, and MMP-9, decreasing amyloid- (A)-induced retinal pigment epithelial barrier disruption. Additionally, SRT1720 increases VEGF secretion and promotes migration and metastasis of breast cancer cells in vitro and in vivo.; Purity: 98%; Molecular Weight: 506.02, 100 mg